(1 - 18 von 24
)
Grünenthal und die KU Leuven bündeln ihre Kräfte zur Entwicklung...
www.ots.at
Und Dr. Patrick Chaltin, Managing Director CD3, ergänzte: "Die ... finden Sie unter www.grunenthal.com Folgen Sie uns auf LinkedIn: @ ...
Neues europäisches Zentrum für Wirkstoff-Screening und...
analytik.news
Das neue Unternehmen, die Hit Discovery Constance GmbH (
Alliance Aims to Accelerate Academic Drug Discovery | GEN - Genetic...
www.genengnews.com
research efforts if needed,” Patrick Chaltin, Ph.D., managing director of The
Centre ...
Grünenthal and KU Leuven Join Forces to Develop an Innovative...
www.prnewswire.co.uk
Patrick Chaltin, Managing Director CD3 added: "The fact that pain is such a widespread health ... Follow us on LinkedIn "Grunenthal Group".
CD3 and VIB speed up in research for biomarker-defined ...
www.health-house.be
Patrick Chaltin, Managing Director of CD3 at KU Leuven added: "This agreement demonstrates CD3's strong drive to translate promising scientific insights ... › news
EPO - John Starrett, Joanne Bronson, John Martin, Muzammil Mansuri...
www.epo.org
“Not many patients like injections, and the effect is counter-productive,” said Patrick Chaltin, technology officer at the Rega Medical Institute.
Janssen Announces Novel Mechanism of Action that Shows ...
www.streetinsider.com
... Suzanne Kaptein at the KU Leuven Rega Institute and Patrick Chaltin at Centre for Drug Design and Discovery (CD3), as well as their respective teams, ... › Jan...
John Starrett, Joanne Bronson, John Martin, Muzammil Mansuri and ...
www.epo.org
“Not many patients like injections, and the effect is counter-productive,” said Patrick Chaltin, technology officer at the Rega Medical Institute. › finalists › St...
Opinions: Right from the start - EATRIS
eatris.eu
Matthias Stein-Gerlach from the Lead Discovery Center, a spin off from Max Planck Innovation, and Patrick Chaltin from CD3, an initiative from KULeuven and ... › News
KU Leuven launches €60 million fund for innovative biomedical...
sciencebusiness.net
KU Leuven’s Centre for Drug Design and Discovery closes €60 million fund to turn academic research into new medicines
Beactica, VIB and CD3 announce drug discovery alliance ...
www.beactica.se
— ... by universities and small biotech companies into promising molecules for new medicines”, said Patrick Chaltin, Managing Director at CD3. › press › b...
Pfizer Inks Exclusive Deal with K.U. Leuven for New Mechanism of...
www.genengnews.com
Small molecules block viral integration of genetic material into host cells.
K U Leuven and EIF invest €16m in CD3
www.manufacturingchemist.com
— ... cancer, arthritis, asthma, Dengue virus infections and Alzheimer's disease,' said Patrick Chaltin, managing director of CD3. › ...
KU Leuven develops very potent antiviral against dengue
www.eurekalert.org
— This may change thanks to the breakthrough discovery of teams led by Johan Neyts (Rega Institute at KU Leuven) and Patrick Chaltin ... This may change thanks to the breakthrough discovery of teams led by Johan Neyts (Rega Institute at KU Leuven) and Patrick Chaltin (CD3/CISTIM Leuven vzw), ... › news-... › multi...
KU Leuven researchers develop an ultrapotent inhibitor of ...
www.news-medical.net
— Patrick Chaltin: "In the future, we want to develop a range of antiviral molecules against the different virus families with pandemic potential, ... › news
Potent Dengue Antiviral Effective against All Known Variants
www.genengnews.com
— There are four types of dengue viruses, and the molecule needed to be equally effective against all four of them, added Patrick Chaltin, ... › news
Wellcome Trust funds dengue fever research in | EurekAlert!
www.eurekalert.org
The Laboratory for Virology and Experimental Chemotherapy and the Centre for Drug Design and Discovery at K.U.Leuven will receive a total of 2.8 million euro...
sortiert nach Relevanz / Datum